These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22529247)

  • 1. Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau.
    Desikan RS; McEvoy LK; Thompson WK; Holland D; Brewer JB; Aisen PS; Sperling RA; Dale AM;
    Arch Neurol; 2012 Jun; 69(6):709-13. PubMed ID: 22529247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.
    Snider BJ; Fagan AM; Roe C; Shah AR; Grant EA; Xiong C; Morris JC; Holtzman DM
    Arch Neurol; 2009 May; 66(5):638-45. PubMed ID: 19433664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.
    Okonkwo OC; Alosco ML; Griffith HR; Mielke MM; Shaw LM; Trojanowski JQ; Tremont G;
    Arch Neurol; 2010 Jun; 67(6):688-96. PubMed ID: 20558388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of clusterin in amyloid-β-associated neurodegeneration.
    Desikan RS; Thompson WK; Holland D; Hess CP; Brewer JB; Zetterberg H; Blennow K; Andreassen OA; McEvoy LK; Hyman BT; Dale AM;
    JAMA Neurol; 2014 Feb; 71(2):180-7. PubMed ID: 24378367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
    Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.
    Desikan RS; McEvoy LK; Holland D; Thompson WK; Brewer JB; Aisen PS; Andreassen OA; Hyman BT; Sperling RA; Dale AM;
    AJNR Am J Neuroradiol; 2013 Mar; 34(3):505-10. PubMed ID: 22976236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
    Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
    JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-β associated volume loss occurs only in the presence of phospho-tau.
    Desikan RS; McEvoy LK; Thompson WK; Holland D; Roddey JC; Blennow K; Aisen PS; Brewer JB; Hyman BT; Dale AM;
    Ann Neurol; 2011 Oct; 70(4):657-61. PubMed ID: 22002658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment.
    Okonkwo OC; Mielke MM; Griffith HR; Moghekar AR; O'Brien RJ; Shaw LM; Trojanowski JQ; Albert MS;
    Arch Neurol; 2011 Jan; 68(1):113-9. PubMed ID: 21220682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
    Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
    Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments.
    Babulal GM; Chen L; Murphy SA; Carr DB; Morris JC
    Neurology; 2024 Jun; 102(12):e209426. PubMed ID: 38776513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies.
    Rådestig MA; Skoog J; Zetterberg H; Kern J; Zettergren A; Sacuiu S; Waern M; Wetterberg H; Blennow K; Skoog I; Kern S
    J Alzheimers Dis; 2021; 79(1):225-235. PubMed ID: 33216028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
    Stomrud E; Hansson O; Zetterberg H; Blennow K; Minthon L; Londos E
    Arch Neurol; 2010 Feb; 67(2):217-23. PubMed ID: 20142530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.